http://www.amgennews.com/index.php en piroc@piroc.com Copyright 2008 2008-05-06T06:01:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_participate_in_chmp_meeting_in_may/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_participate_in_chmp_meeting_in_may/#When:06:01:00Z THOUSAND OAKS, Calif. – May 6, 2008 – Amgen (NASDAQ:AMGN) today announced that the European Committee for Medicinal Products for Human Use (CHMP) has requested Amgen and other erythropoiesis-stimulating agent (ESA) marketing authorization holders to participate in a closed meeting of the Scientific Advisory Group on Oncology (SAG-O) on May 15. Press Releases 2008-05-06T06:01:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_to_participate_in_dodac_meeting_in_june/ http://www.amgennews.com/index.php/2008NewsService/amgen_to_participate_in_dodac_meeting_in_june/#When:06:15:00Z THOUSAND OAKS, Calif. – May 1, 2008 – Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has asked the Company to participate in a meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee (DODAC) on June 18, 2008. The DODAC will review data supporting the supplemental Biologic License Application (sBLA) submitted by Amgen for the use of ENBREL in treating pediatric patients with chronic moderate to severe plaque psoriasis, who are inadequately controlled with topical therapy or who have received systemic therapy or phototherapy. Press Releases, Product News 2008-05-01T06:15:00+00:00 http://www.amgennews.com/index.php/2008NewsService/bob_bradway_to_present_at_the_morgan_stanley_global_healthcare_unplugged_co/ http://www.amgennews.com/index.php/2008NewsService/bob_bradway_to_present_at_the_morgan_stanley_global_healthcare_unplugged_co/#When:14:05:00Z THOUSAND OAKS, Calif., Apr 30, 2008 – Amgen (NASDAQ:AMGN) Executive Vice President and CFO Bob Bradway will present at the Morgan Stanley Global Healthcare Unplugged Conference on Thursday, May 1, 2008 beginning at 10:00 a.m. Eastern Time. Live audio of the presentation will be available over the Internet and can be accessed from Amgen’s Web site, http://www.amgen.com, under Investors. Press Releases 2008-04-30T14:05:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_q1_2008_results/ http://www.amgennews.com/index.php/2008NewsService/amgen_q1_2008_results/#When:17:15:00Z First Quarter 2008 Revenue Decreased 2 percent to $3.6 Billion; First Quarter 2008 GAAP Earnings Per Share Increased 11 percent to $1.04 THOUSAND OAKS, Calif., Apr 24, 2008 – Amgen (NASDAQ:AMGN) reported adjusted earnings per share (EPS), excluding stock option expense and certain other expenses, of $1.12 for the first quarter of 2008, an increase of 4 percent compared to $1.08 for the first quarter of 2007. Adjusted net income, excluding stock option expense and certain other expenses, decreased 4 percent to $1,218 million in the first quarter of 2008 compared to $1,270 million in the first quarter of 2007. Stock option expense on a per share basis totaled 2 cents and 3 cents for the first quarter of 2008 and 2007, respectively. Press Releases 2008-04-24T17:15:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2008_first_quarter_financial_results/ http://www.amgennews.com/index.php/2008NewsService/amgen_announces_webcast_of_2008_first_quarter_financial_results/#When:05:00:00Z THOUSAND OAKS, Calif. – April 16, 2008 – Amgen (NASDAQ:AMGN) today announced that it plans to report its first quarter financial results on Thursday, April 24, 2008 after the close of the financial markets. The announcement will be followed by a conference call with the investment community at 2 p.m. Pacific Time. Participating in the call from Amgen will be Kevin Sharer, chairman and chief executive officer, and other members of Amgen’s senior management team. Press Releases 2008-04-16T05:00:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_presents_preclinical_and_clinical_data_from_oncology_programs/ http://www.amgennews.com/index.php/2008NewsService/amgen_presents_preclinical_and_clinical_data_from_oncology_programs/#When:05:00:00Z SAN DIEGO – April 15, 2008 – Amgen (NASDAQ:AMGN) today announced data generated by the company’s robust oncology research and development programs in the areas of apoptosis (programmed cell death) and cell growth regulation. The data, presented at the American Association for Cancer Research (AACR) Annual Meeting in San Diego were from five preclinical studies evaluating anti-tumor activity, pharmacodynamics, and potential pre-clinical and clinical biomarkers for investigational molecules AMG 655, AMG 479 and AMG 102. Press Releases, Pipeline News 2008-04-15T05:00:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_scientist_visits_los_angeles_classroom_during_teach_for_america_week/ http://www.amgennews.com/index.php/2008NewsService/amgen_scientist_visits_los_angeles_classroom_during_teach_for_america_week/#When:13:35:00Z THOUSAND OAKS, Calif. (April 14, 2008) – For the 13 million children growing up in poverty in this country today, disparities in educational outcomes will limit opportunities in life. This week, Dr. Joseph Miletich, senior vice president of Research and Development at Amgen, will be one of more than 150 distinguished guest teachers in classrooms across the nation participating in Teach For America Week, an annual event that raises awareness about the challenges facing students in low-income communities and the promise these students have to offer. Philanthropy, Press Releases 2008-04-14T13:35:00+00:00 http://www.amgennews.com/index.php/2008NewsService/early_data_on_amgens_anti_angiogenesis_pipeline/ http://www.amgennews.com/index.php/2008NewsService/early_data_on_amgens_anti_angiogenesis_pipeline/#When:18:29:00Z SAN DIEGO – April 13, 2008 – Amgen (NASDAQ:AMGN), today announced results from preclinical studies suggesting a significantly greater reduction in tumor growth when AMG 386, a recombinant Fc-peptide fusion protein (peptibody) designed to bind angiopoietins 1 and 2, thereby inhibiting Tie2 dependent stimulation of endothelial cells, was combined with either of two vascular endothelial growth factor (VEGF) inhibitors—bevacizumab or motesanib diphosphate (AMG 706)—compared with either treatment alone (p less than 0.05). Angiopoietins, together with VEGFs, are key cytokines that regulate neovascularization. The results of preclinical studies that investigated the growth of human colon tumor cells in this combination were presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting in San Diego. Press Releases, Pipeline News 2008-04-13T18:29:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_teach_for_america_summit/ http://www.amgennews.com/index.php/2008NewsService/amgen_teach_for_america_summit/#When:13:06:00Z PALO ALTO, Calif., April 11, 2008 – How will we improve math and science education in our country? What steps can we take to lay an early foundation for student success in these subject areas? How can we incorporate technology into the classroom to increase student achievement? These are some of the questions on tap for the Amgen-Teach For America Mathematics and Science Summit, to be held April 12 at Stanford University in Palo Alto, Calif. The second annual event will bring together Teach For America corps members, alumni, and leaders from a variety of sectors to consider key strategies for advancing mathematics and science education, inspire greater involvement in support of math and science education, and maximize connections to professional resources and opportunities. Philanthropy, Press Releases 2008-04-11T13:06:00+00:00 http://www.amgennews.com/index.php/2008NewsService/amgen_statement_on_romiplostim_pdufa_date/ http://www.amgennews.com/index.php/2008NewsService/amgen_statement_on_romiplostim_pdufa_date/#When:21:52:00Z THOUSAND OAKS, Calif. – April 8, 2008 – Amgen Inc. (NASDAQ:AMGN) today issued the following statement on the Prescription Drug User Fee Act (PDUFA) date for romiplostim. Press Releases, Pipeline News 2008-04-08T21:52:00+00:00